Balancing Growth Prospects and Regulatory Challenges: A Hold Rating on PTC Therapeutics
Joseph Schwartz, an analyst from Leerink Partners, reiterated the Hold rating on PTC Therapeutics (PTCT – Research Report). The ...
NBC News16h
Once thought a haven from Israeli strikes, a Christian town in Lebanon is now a scene of carnage
Just last week, the area “was calm; everything was quiet,” Illy Edwan told NBC News as he surveyed the wreckage of his villa, which was reduced to rubble in the blast, its insulation and inner ...
PTC Therapeutics price target raised to $43 from $31 at Barclays
Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $43 from $31 and keeps an Equal Weight rating on the shares. The ...